Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer

被引:163
作者
Danese, S. [2 ]
Mantovani, A. [1 ]
机构
[1] Ist Clin Humanitas IRCCS, Lab Inflammat & Immunol, I-20089 Milan, Italy
[2] Div Gastroenterol, Inflammatory Bowel Dis Unit, Milan, Italy
关键词
inflammation; colon cancer; chemokines; TUMOR-NECROSIS-FACTOR; TOLL-LIKE RECEPTORS; IKK/NF-KAPPA-B; BLOCKING TNF-ALPHA; COLON-CANCER; ULCERATIVE-COLITIS; COLORECTAL-CANCER; EPITHELIAL-CELLS; MOUSE MODEL; INTERLEUKIN-10-DEFICIENT MICE;
D O I
10.1038/onc.2010.109
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Colon cancer represents a paradigm for the connection between inflammation and cancer in terms of epidemiology and mechanistic studies in preclinical models. Key components of cancer promoting inflammation include master transcription factors (for example, nuclear factor kappa B, STAT3), proinflammatory cytokines (for example, tumor necrosis factor, interleukin-6 (IL-6)), cyclooxygenase-2 and selected chemokines (for example, CCL2). Of no less importance are mediators that keep inflammation in check, including IL-10, transforming growth factor beta, toll-like receptor and the IL-1 receptor inhibitor TIR8/SIGIRR, and the chemokine decoy and scavenger receptor D6. Dissection of molecular pathways involved in colitis-associated cancer may offer opportunities for innovative therapeutic strategies. Oncogene (2010) 29, 3313-3323; doi:10.1038/onc.2010.109; published online 19 April 2010
引用
收藏
页码:3313 / 3323
页数:11
相关论文
共 116 条
[11]   TGF-beta as a T cell regulator in colitis and colon cancer [J].
Becker, C ;
Fantini, MC ;
Neurath, MF .
CYTOKINE & GROWTH FACTOR REVIEWS, 2006, 17 (1-2) :97-106
[12]   Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses [J].
Berg, DJ ;
Davidson, N ;
Kuhn, R ;
Muller, W ;
Menon, S ;
Holland, G ;
ThompsonSnipes, L ;
Leach, MW ;
Rennick, D .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (04) :1010-1020
[13]  
Bernstein CN, 2001, CANCER-AM CANCER SOC, V91, P854, DOI 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO
[14]  
2-Z
[15]  
Betti M, 2006, ANN ONCOL, V17, P235
[16]   Long-term safety of Infliximab for the treatment of inflammatory bowel disease: does blocking TNFα reduce colitis-associated colorectal carcinogenesis? [J].
Biancone, L. ;
Petruzziello, C. ;
Calabrese, E. ;
Zorzi, F. ;
Naccarato, P. ;
Onali, S. ;
Pallone, F. .
GUT, 2009, 58 (12) :1703-1703
[17]   IKK/NF-κB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis [J].
Bollrath, Julia ;
Greten, Florian R. .
EMBO REPORTS, 2009, 10 (12) :1314-1319
[18]   gp130-Mediated Stat3 Activation in Enterocytes Regulates Cell Survival and Cell-Cycle Progression during Colitis-Associated Tumorigenesis [J].
Bollrath, Julia ;
Phesse, Toby J. ;
von Burstin, Vivian A. ;
Putoczki, Tracy ;
Bennecke, Moritz ;
Bateman, Trudie ;
Nebelsiek, Tim ;
Lundgren-May, Therese ;
Canli, Oezge ;
Schwitalla, Sarah ;
Matthews, Vance ;
Schmid, Roland M. ;
Kirchner, Thomas ;
Arkan, Melek C. ;
Ernst, Matthias ;
Greten, Florian R. .
CANCER CELL, 2009, 15 (02) :91-102
[19]   Differential recognition and scavenging of native and truncated macrophage-derived chemokine (macrophage-derived chemokine/CC chemokine ligand 22) by the D6 decoy receptor [J].
Bonecchi, R ;
Locati, M ;
Galliera, E ;
Vulcano, M ;
Sironi, M ;
Fra, AM ;
Gobbi, M ;
Vecchi, A ;
Sozzani, S ;
Haribabu, B ;
Van Damme, J ;
Mantovani, A .
JOURNAL OF IMMUNOLOGY, 2004, 172 (08) :4972-4976
[20]   Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials [J].
Bongartz, T ;
Sutton, AJ ;
Sweeting, MJ ;
Buchan, I ;
Matteson, EL ;
Montori, V .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (19) :2275-2285